Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial

Journal:
The Lancet Oncology
Published:
Affiliations:
31
Authors:
29
Institutions Authors Share
German Hodgkin Study Group (GHSG), Germany
2.500000
0.09
University Hospital of Cologne, Germany
2.500000
0.09
University of Cologne (UoC), Germany
2.000000
0.07
Center for Integrated Oncology Aachen Bonn Köln Düsseldorf (CIO), Germany
2.000000
0.07
Nordic Lymphoma Group (NLG), Denmark
1.500000
0.05
Swiss Group for Clinical Cancer Research (SAKK), Switzerland
1.000000
0.03
University of Tübingen (Uni Tübingen), Germany
1.000000
0.03
Charité - University Medicine Berlin, Germany
1.000000
0.03
Amsterdam UMC, Netherlands
1.000000
0.03
University Medical Center Hamburg-Eppendorf (UKE), UHH, Germany
1.000000
0.03
Royal Adelaide Hospital (RAH), Australia
1.000000
0.03
Klinikum Chemnitz gGmbH, Germany
1.000000
0.03
Klinikum Bremen-Mitte, Germany
1.000000
0.03
University Hospital of Munich (KUM), LMU, Germany
1.000000
0.03
Robert Bosch Hospital (RBK), Germany
1.000000
0.03
Heidelberg University (Uni Heidelberg), Germany
1.000000
0.03
Essen University Hospital, Germany
1.000000
0.03
Hanusch Hospital, MUW, Austria
1.000000
0.03
Ulm University Medical Center, Germany
1.000000
0.03
Bern University Hospital, Switzerland
0.500000
0.02
Oncology Institute of Southern Switzerland (IOSI), Switzerland
0.500000
0.02
Oslo University Hospital (OUS), Norway
0.500000
0.02
Uppsala University (UU), Sweden
0.500000
0.02
Aarhus University Hospital, Denmark
0.500000
0.02
Australasian Leukaemia and Lymphoma Group (ALLG), Australia
0.333333
0.01
Salzburg Cancer Research Institute (SCRI), Austria
0.333333
0.01
Arbeitsgemeinschaft medikamentöse Tumortherapie (AGMT), Austria
0.333333
0.01
Paracelsus Medical University (PMU), Austria
0.333333
0.01
University of New South Wales (UNSW Sydney), Australia
0.333333
0.01
Prince of Wales Hospital, Australia
0.333333
0.01